The effect of an oral nutritional supplement enriched with fish oil on weight loss in patients with pancreatic cancer

被引:296
作者
Barber, MD
Ross, JA
Voss, AC
Tisdale, MJ
Fearon, KCH [1 ]
机构
[1] Univ Edinburgh, Royal Infirm Edinburgh, Dept Surg, Edinburgh EH8 9JA, Midlothian, Scotland
[2] Abbott Labs, Ross Prod Div, Columbus, OH 43215 USA
[3] Aston Univ, Dept Pharmaceut Sci, Birmingham B4 7ET, W Midlands, England
关键词
pancreatic cancer; cachexia; eicosapentaenoic acid; docosahexaenoic acid; fish oil; nutritional supplementation;
D O I
10.1038/sj.bjc.6690654
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies have suggested that administration of oral eicosapentaenoic acid (EPA) will stabilize weight in patients with advanced pancreatic cancer. The aim of the present study was to determine ii a combination of EPA with a conventional oral nutritional supplement could produce weight gain in these patients. Twenty patients with unresectable pancreatic adenocarcinoma were asked to consume two cans of a fish oil-enriched nutritional supplement per day in addition to their normal food intake, Each can contained 310 kcal, 16.1 g protein and 1.09 g EPA. Patients were assessed for weight, body composition, dietary intake, resting energy expenditure (REE) and performance status. Patients consumed a median of 1.9 cans day(-1), All patients were losing weight at baseline at a median rate of 2.9 kg month(-1). After administration of the fish oil-enriched supplement, patients had significant weight-gain at both 3 (median 1 kg, P = 0.024) and 7 weeks (median 2 kg, P = 0.033), Dietary intake increased significantly by almost 400 kcal day(-1) (P = 0.002), REE per kg body weight and per kg lean body mass fell significantly. Performance status and appetite were significantly improved at 3 weeks. In contrast to previous studies of oral conventional nutritional supplements in weight-losing cancer patients, this study suggests that an EPA-enriched supplement may reverse cachexia in advanced pancreatic cancer.
引用
收藏
页码:80 / 86
页数:7
相关论文
共 39 条
  • [1] Ahlgren JD, 1996, SEMIN ONCOL, V23, P241
  • [2] BARBER MD, 1997, PROSTAGLANDINS LEUKO, V57, P204
  • [3] BECK SA, 1991, CANCER RES, V51, P6089
  • [4] Cohn S H, 1982, Nutr Cancer, V4, P107, DOI 10.1080/01635588209513746
  • [5] PROGNOSTIC EFFECT OF WEIGHT-LOSS PRIOR TO CHEMOTHERAPY IN CANCER-PATIENTS
    DEWYS, WD
    BEGG, C
    LAVIN, PT
    BAND, PR
    BENNETT, JM
    BERTINO, JR
    COHEN, MH
    DOUGLASS, HO
    ENGSTROM, PF
    EZDINLI, EZ
    HORTON, J
    JOHNSON, GJ
    MOERTEL, CG
    OKEN, MM
    PERLIA, C
    ROSENBAUM, C
    SILVERSTEIN, MN
    SKEEL, RT
    [J]. AMERICAN JOURNAL OF MEDICINE, 1980, 69 (04) : 491 - 497
  • [6] A RANDOMIZED STUDY OF ORAL NUTRITIONAL SUPPORT VERSUS AD-LIB NUTRITIONAL INTAKE DURING CHEMOTHERAPY FOR ADVANCED COLORECTAL AND NON-SMALL-CELL LUNG-CANCER
    EVANS, WK
    NIXON, DW
    DALY, JM
    ELLENBERG, SS
    GARDNER, L
    WOLFE, E
    SHEPHERD, FA
    FELD, R
    GRALLA, R
    FINE, S
    KEMENY, N
    JEEJEEBHOY, KN
    HEYMSFIELD, S
    HOFFMAN, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) : 113 - 124
  • [7] FALCONER JS, 1995, CANCER, V75, P2077, DOI 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO
  • [8] 2-9
  • [9] CYTOKINES, THE ACUTE-PHASE RESPONSE, AND RESTING ENERGY-EXPENDITURE IN CACHECTIC PATIENTS WITH PANCREATIC-CANCER
    FALCONER, JS
    FEARON, KCH
    PLESTER, CE
    ROSS, JA
    CARTER, DC
    [J]. ANNALS OF SURGERY, 1994, 219 (04) : 325 - 331
  • [10] EFFECT OF EICOSAPENTAENOIC ACID AND OTHER FATTY-ACIDS ON THE GROWTH IN-VITRO OF HUMAN PANCREATIC-CANCER CELL-LINES
    FALCONER, JS
    ROSS, JA
    FEARON, KCH
    HAWKINS, RA
    ORIORDAIN, MG
    CARTER, DC
    [J]. BRITISH JOURNAL OF CANCER, 1994, 69 (05) : 826 - 832